2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-19740
    BIA 10-2474 1233855-46-3 99.39%
    BIA 10-2474 is an inhibitor of fatty acid amide hydrolase (FAAH) with IC50 values of 50 to 70mg/kg in various rat brain regions.
    BIA 10-2474
  • HY-104005
    ML335 825658-06-8 99.63%
    ML335 is a selective activator of both TREK-1 and TREK-2.
    ML335
  • HY-107416
    RHC 80267 83654-05-1 99.41%
    RHC 80267 (U-57908) is a potent and selective inhibitor of diacylglycerol lipase (DAGL) (with IC50 of 4 μM in canine platelets). RHC-80267 inhibits cholinesterase activity with an IC50 of 4 μM, thereby enhancing the relaxation evoked by acetylcholine. RHC 80267 also inhibits COX and the hydrolysis of phosphatidylcholine (PC).
    RHC 80267
  • HY-108006
    Mirogabalin besylate 1138245-21-2 ≥98.0%
    Mirogabalin besylate is a selective and orally available ligand for the α2δ subunit of voltage-gated calcium channels, with Kds of 13.5 nM, 22.7 nM, 27 nM, and 47.6 nM for human α2δ-1, human α2δ-2, rat α2δ-1, and rat α2δ-2, respectively.
    Mirogabalin besylate
  • HY-108714
    NGP555 1304630-27-0 98.77%
    NGP555 is a γ-secretase modulator. NGP555 Lowers the Amyloid Biomarker Aβ42.
    NGP555
  • HY-114331
    DLK-IN-1 1620574-24-4 99.18%
    DLK-IN-1 (Compound 14) is an orally active, blood-brain barrier-penetrable and selective inhibitor of dual leucine zipper kinase (DLK, MAP3K12) with a Ki value of 3 nM. DLK-IN-1 inhibits Flt3, PAK4, STK33 and TrkA. DLK-IN-1 reduces p-c-Jun. DLK-IN-1 can be used in Alzheimer's disease research.
    DLK-IN-1
  • HY-125999
    EPI-589 1147883-03-1 99.53%
    EPI-589, a quinone derivative, is a safe and well tolerated oxidoreductase enzyme inhibitor and a free radical scavenger, with blood-brain barrier permeable and orally available. EPI-589 is a redox-active neuroprotectant that effectively delays the symptoms of motor neuron disease in wobbler mice. EPI-589 can be used in amyotrophic lateral sclerosis (ALS) research.
    EPI-589
  • HY-130258
    LC3-mHTT-IN-AN1 486443-73-6
    LC3-mHTT-IN-AN1 (Compound AN1) is a mHTT-LC3 linker compound, which interacts with both mutant huntingtin protein (mHTT) and LC3B but not with wtHTT or irrelevant control proteins. LC3-mHTT-IN-AN1 reduces the levels of mHTT in an allele-selective manner in cultured Huntington disease (HD) mouse neurons.
    LC3-mHTT-IN-AN1
  • HY-136208
    TAN-452 892039-23-5 99.44%
    TAN-452 is an orally active, selective peripherally acting δ-opioid receptor (DOR) antagonist with a Ki of 0.47 nM and a Kb of 0.21 nM. TAN-452 is an antagonist for μ-opioid receptor (MOR; Ki=36.56 nM and Kb=9.43 nM) and κ-opioid receptor (KOR; Ki=5.31 nM and Kb=7.18 nM). TAN-452, a derivative of Naltrindole, demonstrates low brain penetrability and attenuates morphine-induced side effects without affecting pain control.
    TAN-452
  • HY-144399
    CD33 splicing modulator 1 2762547-05-5 99.55%
    CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 has the potential for the research of neurodegenerative disease including Alzheimer's disease.
    CD33 splicing modulator 1
  • HY-144634
    DDO-7263 2254004-96-9 99.83%
    DDO-7263, a 1,2,4-Oxadiazole derivative, is a potent Nrf2-ARE activator. DDO-7263 upregulates Nrf2 through binding to Rpn6 to block the assembly of 26S proteasome and the subsequent degradation of ubiquitinated Nrf2. DDO-7263 induces Nrf2 translocation into the nucleus. DDO-7263 inhibits of NLRP3 inflammasome activation. DDO-7263 exerts anti-inflammatory activity and has the potential for neurodegenerative diseases research, such as Parkinson's disease (PD).
    DDO-7263
  • HY-148089A
    Eplontersen sodium 2131025-75-5
    Eplontersen sodium the sodium salt form of Eplontersen (HY-148089). Eplontersen sodium is a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases.
    Eplontersen sodium
  • HY-B0151S2
    Pregnenolone-d4-1 61574-54-7 ≥98.0%
    Pregnenolone-d4-1 is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication[1][2]. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].
    Pregnenolone-d4-1
  • HY-17590
    Radafaxine hydrochloride 106083-71-0 99.01%
    Radafaxine hydrochloride (GW-353162A) is a DAT (dopamine transporter) and NET(norepinephrine transporter) transporters inhibitor, and nAChR family modulator.
    Radafaxine hydrochloride
  • HY-103237
    L-Adenosine 3080-29-3
    L-Adenosine is a metabolically stable enantiomeric analog and also is a potential probe. L-Adenosine has weakly inhibitory adenosine deaminase (ADA) activity with an Ki value of 385 μM. L-Adenosine can be used for the research of adenosine uptake and accumulation.
    L-Adenosine
  • HY-117727
    Leriglitazone 146062-44-4 99.23%
    Leriglitazone (MIN-102; Hydroxypioglitazone) is an orally active and a BBB-penatrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases.
    Leriglitazone
  • HY-120596
    PPARδ/γ agonist 1 sodium 1258076-66-2 99.91%
    PPARδ/γ agonist 1 sodium is a chemically unique and brain penetrant dual PPAR delta/gamma agonist. PPARδ/γ agonist 1 sodium can be used for the research of Alzheimer’s disease.
    PPARδ/γ agonist 1 sodium
  • HY-133555
    mGluR2 antagonist 1 1432728-49-8 99.31%
    mGluR2 antagonist 1 is a highly potent, orally bioavailable and selective class of mGluR2 negative allosteric modulator (IC50 of 9 nM) with excellent brain permeability.
    mGluR2 antagonist 1
  • HY-139589
    Zaloglanstat 1513852-12-4 98.50%
    Zaloglanstat (ISC-27864) is a selective and orally active inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1) with an IC50 of 5 nM. Zaloglanstat inhibits PGE2 release of IC50 at 161 nM and 154 nM in whole blood of pigs and dogs, respectively. Zaloglanstat can be used in studies of asthma, osteoarthritis and neurodegenerative diseases.
    Zaloglanstat
  • HY-144290
    ARN25068 2649882-80-2 99.66%
    ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation.
    ARN25068
Cat. No. Product Name / Synonyms Application Reactivity